In a strategic move blending technological innovation with environmental consciousness, SGD Pharma has invested over €20 million to advance its facility in Zhanjiang, China. This significant refurbishment is not merely about upgrading the equipment but is part of a greener manifesto—committing to
In the ever-evolving landscape of pharmaceuticals, the debate over regulatory data protection (RDP) is intensifying. As the Belgian Presidency of the Council of the EU approaches its twilight, policymakers are grappling with how to balance the imperatives of fostering pharmaceutical innovation with
The landscape of biopharmaceutical manufacturing in Ireland has recently welcomed an impressive addition with the inauguration of the National Institute for Bioprocessing Research and Training's (NIBRT) new facility. This state-of-the-art establishment in Dublin, conceived with a robust €21 million
In a significant move aimed at boosting the development of cell and gene therapies, Bionova Scientific, a part of the Asahi Kasei Group, has announced an ambitious $100 million investment. This investment will see the creation of a new state-of-the-art plasmid DNA (pDNA) production facility in The
In the rapidly-changing environment of the pharmaceutical industry, the innovative stride of Pharma 4.0 heralds a new era of drug production. This pivotal shift to smart manufacturing aligns with the principles of Industry 4.0, embedding digitalization and cutting-edge technology to meet the
In the dynamic realm of biopharmaceutical investments, the diverging analyst ratings for Can-Fite BioPharma (NYSE: CANF) underscore the complex calculus of betting on drug development firms. The stock analysis firm StockNews.com has planted its flag with a "hold" rating, signaling a cautious stance
